常见变异型免疫缺陷病的自身免疫风湿病学表现及基因检测概述
本文综述原发性免疫缺陷病(PIDs)中以常见变异型免疫缺陷病(CVID)为代表的自身免疫风湿病学表现,强调部分患者以自身免疫或炎症后遗症为首发表现、可在第六或第七个十年才出现症状,需早期识别以避免免疫抑制导致的机会性感染,并概述基因检测对个体化治疗及家系筛查的意义。
要点
- CVID等PIDs患者可以自身免疫肌肉骨骼表现为首发就诊于风湿免疫科。
- 对这类免疫受损患者使用免疫抑制可能导致危及生命的机会性感染。
- 皮下或静脉免疫球蛋白替代(SCIG/IVIG)或预防性抗生素可减轻上述风险。
核心结论
- 部分PIDs患者以自身免疫或炎症后遗症为首发临床表现,识别PID对避免免疫抑制相关机会性感染至关重要。
- 许多此类疾病存在潜在遗传缺陷,可能有个体化治疗针对特定突变,从而避免或减轻广谱免疫抑制的需要。
- 识别遗传缺陷对患者及可能因环境触发(如病毒感染)而发病的受累家庭成员均有深远意义。
研究设计与样本
- 本文为综述,由三个部分组成:PIDs概述(重点为CVID)、PIDs的基因检测、以及这些疾病在风湿免疫科的临床表现。
主要发现
- PIDs罕见,多为单基因病,可就诊于多个专科;多数以感染为主,但部分个体可以自身免疫或炎症后遗症为首发表现。
- 识别PID患者可能具有挑战性,部分患者可在生命较晚阶段才出现表现,这在CVID中常见,症状可在第六甚至第七个十年才开始。
- 包括CVID在内的一些PIDs患者可最初以自身免疫肌肉骨骼表现就诊于风湿免疫科。
- 这些患者必须被及时识别,因为免疫抑制可能在这类免疫受损个体中导致危及生命的机会性感染。
- 这些风险可通过事先使用皮下或静脉免疫球蛋白替代(SCIG/IVIG)或预防性抗生素来减轻。
关键数值与推荐
- 潜在PID的临床线索包括反复感染、早发严重或多发自身免疫病以及相关家族史。
- 早期转诊临床免疫学家有助于恰当的诊断评估和启动SCIG/IVIG免疫球蛋白替代等治疗。
临床怎么用
- 风湿免疫科医生应认识PIDs(包括CVID)可以自身免疫肌肉骨骼表现为初始就诊表现。
- 对疑似PID患者应及时识别,因免疫抑制可能带来危及生命的机会性感染风险。
- 可通过事先SCIG/IVIG免疫球蛋白替代或预防性抗生素减轻上述感染风险。
- 识别潜在遗传缺陷可能为特定突变提供个体化治疗,并有助于评估受累家庭成员。
- 反复感染、早发严重或多发自身免疫病及相关家族史提示潜在PID,早期转诊临床免疫学家有助于诊断评估与治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary immunodeficiency Disorders (PIDS) are rare, mostly monogenetic conditions which can present to a number of specialties. Although infections predominate in most PIDs, some individuals can manifest autoimmune or inflammatory sequelae as their initial clinical presentation. Identifying patients with PIDs can be challenging, as some can present later in life. This is often seen in patients with Common Variable Immunodeficiency Disorders (CVID), where symptoms can begin in the sixth or even seventh decades of life. Some patients with PIDs including CVID can initially present to rheumatologists with autoimmune musculoskeletal manifestations. It is imperative for these patients to be identified promptly as immunosuppression could lead to life-threatening opportunistic infections in these immunocompromised individuals. These risks could be mitigated by prior treatment with subcutaneous or intravenous (SCIG/IVIG) immunoglobulin replacement or prophylactic antibiotics. Importantly, many of these disorders have an underlying genetic defect. Individualized treatments may be available for the specific mutation, which may obviate or mitigate the need for hazardous broad-spectrum immunosuppression. Identification of the genetic defect has profound implications not only for the patient but also for affected family members, who may be at risk of symptomatic disease following an environmental trigger such as a viral infection. Finally, there may be clinical clues to the underlying PID, such as recurrent infections, the early presentation of severe or multiple autoimmune disorders, as well as a relevant family history. Early referral to a clinical immunologist will facilitate appropriate diagnostic evaluation and institution of treatment such as SCIG/IVIG immunoglobulin replacement. This review comprises three sections; an overview of PIDs, focusing on CVID, secondly genetic testing of PIDs and finally the clinical presentation of these disorders to rheumatologists.
引用
- Ameratunga R, Woon ST, Leung E, et al. The autoimmune rheumatological presentation of Common Variable Immunodeficiency Disorders with an overview of genetic testing. Semin Arthritis Rheum. 2024. PMID: 38330740. doi:10.1016/j.semarthrit.2024.152387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。